Drug Development
Hepatic CYP isoforms inhibited by mGluR5 antagonists
Published in Hepatitis Weekly, August 16th, 2004
"Characterization of new chemical entities for their potential to produce drug-drug interactions is an important aspect of early drug discovery screening," scientists in California explained.
In a study conducted by M.D. Green and colleagues at Merck Research Laboratories in San Diego, the "potential for three metabotropic glutamate receptor antagonists to interact with recombinant human CYPs was investigated."
"2-Methyl-6-(phenylethenyl) pyridine (SIB-1893), 2-methyl-6-(phenylethynyl) pyridine (MPEP) and 3-[2-methyl-1,3-thiazol-4-yl)...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2004-08-16)
More Articles from Hepatitis Weekly
- Aplastic Anemia
T-cell repertoire returns to normal in HAA recovery - Hepatitis & Cancer
Expression of HCV core protein impairs DNA repair in human hepatoma cells - Hepatitis B Virus
HBV genotypes and precore and core mutants studied in Brazilian patients - Hepatitis C Virus
Enrichment technique to detect hepatitis-specific T cells studied - Hepatitis C Virus
HCV associated with diabetes after kidney transplant in patients on tacrolimus - Cancer Therapy
Pharma company reports progress in aurora kinase program for treatment of cancer - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
